61 Antidiuretic hormone disorders - Milton Keynes Formulary

• Home
• Chapters
  • 1. Gastro-Intestinal System
  • 2. Cardiovascular system
  • 3. Respiratory System
  • 4. Nervous System
  • 5. Infections
  • 6. Endocrine System
  • 7. Obstetrics, Gynaecology and Urinary-tract Disorders
  • 8. Immune System and Malignant Disease
  • 9. Nutrition and Blood
  • 10. Musculoskeletal and Joint Diseases
  • 11. Eye
  • 12. Ear, Nose and Oropharynx
  • 13. Skin
  • 14. Immunological Products and Vaccines
  • 15. Anaesthesia
  • 16 Wound Management
  • 17. Miscellaneous Preparations
• Drugs
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
• MK Prescribing Advisory Group (MKPAG)
  • Application Forms
  • MKPAG Ratified Minutes
  • MKPAG Meeting Dates
  • Terms of Reference (ToR)
  • M&TC Minutes
• NICE Adherence Checklist
• GP Prescribing Group
  • Terms of reference
  • Minutes
  • Archived Minutes
• Shared Care Guidelines
• Local & National General Prescribing Information
  • 1. Financial and clinical responsibility for prescribing non-formulary drugs
  • 2. Repeat Prescribing Code of Practice
  • 3. When not to prescribe generically
  • 4. MK CCG Commissioning Policies
  • 5. Borderline Substances (ACBS)
  • 6. Selective List Scheme (SLS)
  • 7. Overseas visitors
  • 8. Travelling abroad
  • 9. Liquid Specials
  • 10. SPS Drug Monitoring Document Oct 2017
  • 11. Medication Information in Practices-November 2017
  • 12. Drugs That Prolong QT Interval
  • 13 Consultation Letter to Schools Nurseries-June 2017
  • 14 Letter to parents re changes in prescribing
  • 15. Self-Care Medicine List
• Biosimilar Position Statement
• Unlicensed Medicines
• Copyright Notice
• Patient Information Leaflets (New)
• About the Formulary Local Decisions
  • About the Joint Formulary
  • Format of the Formulary and Traffic Light Classification
• Newsletters
• Useful Links
• Contact Us

6.1 Antidiuretic hormone disorders

Traffic light status (TLS) explained:

• Green: Routine prescribing within licensed indication
• Amber 1: specialist recommendation followed by GP initiation and continuation
• Amber 2: specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation
• Amber 3: specialist initiation and stabilisation followed by GP continuation
• Amber SCG: specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline
• Red: Hospital or specialist prescribing only

6.1 Antidiuretic hormone disorders

6.1.1 Diabetes insipidus 

Desmopressin            

• Tablets 100 micrograms, 200 micrograms
• Nasal spray 10 micrograms per metered spray
• Injection 4 micrograms in 1mL, 15 micrograms in 1mL 

Chlortalidone (Amber 2)

• Tablets 50mg

Vasopressin        

• Injection 20 units/mL     

6.1.2 Syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Tetracyclines

Demeclocycline hydrochloride

• Capsules, 150mg

Selective vasopressin V₂-receptor antagoinsts

Tolvaptan 

•  Jinarc® tablets 30mg, 90mg             

Notes: 

• NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease (October 2015) 

• Use as per Clinical Commissioning Policy: Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy (Dec 2016)

Return to Chapter: 6. Endocrine System

Last updated by: Dupe Fagbenro on 21-12-2018 11:12